A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.

Inclusion criteria:

• Presence of

  • neovascular (wet) age-related macular degeneration (AMD),
  • visual impairment due to diabetic macular oedema (DME),
  • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) or
  • visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)

• Patients for whom a therapy with Lucentis® is medically indicated.

• Written patients informed consent.

Exclusion criteria:

• As described in the SmPC.
• Preceding intravitreal treatment of the study eye with anti-VEGF drugs in the last three months before enrollment
• Preceding intravitreal treatment of the study eye with steroids

Male and female patients suffering from neovascular eye pathology in real life setting for whom a therapy with Lucentis® is recommended by the treating physician in line with approved indications. Warnings and contraindications have to be taken into account according to the summary of product characteristics (SmPC).